# DDI Study With Multiple-dose LX4211 and Single Dose Digoxin

> **NCT02300350** · PHASE1 · COMPLETED · sponsor: **Lexicon Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Treatment A digoxin
- **DRUG:** Treatment B LX4211
- **DRUG:** Treatment C Digoxin + 400 mg LX4211 administered concomitantly

## Key facts

- **NCT ID:** NCT02300350
- **Lead sponsor:** Lexicon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02300350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02300350, "DDI Study With Multiple-dose LX4211 and Single Dose Digoxin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02300350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*